Influence of olanzapine on serum prolactin levels and BMI in female patients with schizophrenia

Figures & data

Figure 1 Subject flow through the study of olanzapine.

Table 1 Demographics of FEDN with schizophrenia and healthy controls

	FEDN (n=79)	Healthy control (n=35)	T or χ^2	P-value
Age (years)	34.30±8.88	37.03±8.09	1.55	0.12
Education (years)	8.97±3.14	7.94±4.08	1.47	0.14
Height (m)	1.60±0.06	1.59±0.65	0.58	0.56
Weight (kg)	49.75±6.34	51.89±4.13	1.83	0.07
BMI (kg/m^2)	19.51±2.64	20.49±0.88	2.94	0.004
Prolactin (ng/mL)	17.61±2.28	12.12±3.08	10.60	0.001
Subtypes of schizophrenia
Paranoid type	38	N/A
Disorganized type	31	N/A
Residual type	4	N/A
Undifferentiated type	6	N/A
PANSS total score	84.20±12.93	N/A
P subscore	25.46±5.22	N/A
N subscore	18.34±4.53	N/A
G subscore	40.41±6.81	N/A

Notes: P subscore: positive symptom subscore; N subscore: negative symptom subscore; G subscore: general psychopathology subscore; N/A means not applicable.

Abbreviations: BMI, body mass index; FEDN, first-episode drug-naïve; PANSS, Positive and Negative Syndrome Scale.

Table 2 Weight-related, BMI and prolactin effects of olanzapine during 12 weeks of treatment

	Baseline	Week 4	Week 8	Week 12	F or χ^2	P-value
Prolactin	17.61±2.28	67.70±47.45	84.14±47.70	81.01±49.62	42.96	0.001
Weight	49.75±6.34	52.89±6.76	54.50±6.83	55.37±7.20	10.52	0.001
BMI	19.51±2.64	20.74±2.77	21.38±2.82	21.71±2.86	9.60	0.001

Notes: Prolactin are shown in ng/mL; weight are shown in kg; BMI, calculated as (weight in kg)/(height in m²).

Abbreviation: BMI, body mass index.

Figure 2 The change of prolactin during 12-week treatment with olanzapine.

Note: Black squares represent the mean prolactin level.

Figure 3 The change of weight during 12 weeks treatment with olanzapine.

Note: Block dots represent the mean weight level.

Figure 4 The correlation between the increase of BMI and the change in serum prolactin at pre- and posttreatment with olanzapine.

Abbreviation: BMI, body mass index.